Aspen Neuroscience, Inc., is a development stage, private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson disease. Aspen’s therapies are based upon the scientific work of world-renowned stem cell scientist, Dr. Jeanne Loring, who has developed a novel method for autologous neuron replacement.
ANPD001, our lead product, is an autologous, induced pluripotent stem cell (iPSC)-derived dopamine neuron precursor targeting sporadic forms of Parkinson disease. We are currently performing IND-enabling studies of ANPD001 after our pre-IND meeting with the FDA last year and intend to submit an IND to the FDA next year.
Aspen plans to begin nonclinical studies soon for our next pipeline product, ANPD002, which involves gene correction (using either gene editing or viral transduction) of autologous iPSC-based dopamine precursors targeted at familial forms of Parkinson disease (e.g. GBA).
For more information and important updates, please visit http://www.aspenneuroscience.com.